The Cost And Burden Of Chikungunya In The Americas by Bloch, Danielle
Yale University 
EliScholar – A Digital Platform for Scholarly Publishing at Yale 
Public Health Theses School of Public Health 
1-1-2016 
The Cost And Burden Of Chikungunya In The Americas 
Danielle Bloch 
Yale University, bloch.danielle@gmail.com 
Follow this and additional works at: https://elischolar.library.yale.edu/ysphtdl 
Recommended Citation 
Bloch, Danielle, "The Cost And Burden Of Chikungunya In The Americas" (2016). Public Health Theses. 
1022. 
https://elischolar.library.yale.edu/ysphtdl/1022 
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – 
A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an 
authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, 
please contact elischolar@yale.edu. 
 
The Cost and Burden of Chikungunya in the Americas 
 
Danielle Bloch 
Department of Epidemiology of Microbial Diseases 
Yale School of Public Health 
New Haven, Connecticut 
 
 
First Reader: Alison Galvani, PhD 








Background: Chikungunya virus (CHIKV) is a mosquito-transmitted virus that emerged in the 
Caribbean in late 2013 and proceeded to spread throughout the Americas. Acute CHIKV disease 
is characterized by high fever and potentially debilitating arthralgia. In a proportion of cases, 
serious long-term sequelae following acute disease have been reported. These conditions 
primarily include chronic inflammatory rheumatisms, but can also involve depression, 
sensorineural effects, headaches and cognitive delays following neonatal infection. 
Methods: We developed data-driven computational simulation models for acute and long-term 
health conditions associated with CHIKV infection to estimate the economic cost and health 
burden of the 2013–2015 CHIKV epidemic in the Americas, accounting for underreporting of 
cases. We parameterized our models using clinical, epidemiological, and cost data which were 
collected through extensive literature review.  
Findings: Accounting for underreporting, we estimated a total of over 39.9 million cases in the 
Americas, imposing a burden of over 23.8 million disability adjusted life years (DALYs) lost and 
about US$185 billion from a societal perspective. Burden and cost varied substantially by region, 
with the Caribbean accounting for nearly half of the entire disease burden and costs. Over 90% 
of DALYs and 95% of costs were attributable to chronic inflammatory rheumatism. 
Interpretation: Given that there are no effective prevention methods or treatments for 
chikungunya, the emergence of CHIKV in the Americas creates a considerable strain on 
individuals and health systems, both currently and in the future. These results highlight the need 
for increased efforts in vector control to prevent new cases and in investigation into best 
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In late 2013, chikungunya virus (CHIKV) was reported in the Western Hemisphere for the first 
time, on the Caribbean island of St. Martin.1 Transmitted predominantly by the Aedes aegypti 
and Aedes albopictus mosquitoes, the virus quickly spread throughout the Caribbean and the 
Americas. By the end of 2015, more than 1.8 million clinically suspected chikungunya cases in 
45 countries and territories had been reported to the Pan American Health Organization 
(PAHO).2 
 
Symptoms of acute infection with CHIKV frequently include fever, potentially debilitating 
arthralgia, and skin rash.3 In rare instances, complications of acute disease may include 
myocarditis, Guillain-Barré Syndrome, mild hemorrhage, and encephalitis.4 Death in association 
with CHIKV infection is very rare (<0.1% of hospitalized cases), and is more likely to be 
associated with exacerbation of pre-existing chronic medical conditions.5 However, long-term 
morbidity associated with CHIKV infection can be substantial, as 12.7–63.8% of those with 
symptomatic chikungunya report experiencing chronic inflammatory rheumatism, including 
chronic arthritis and arthralgia, beyond the scope of acute infection.5–15 These symptoms can last 
months to years post-acute infection, in rare cases lasting as long as six years.16 Though less 
established, CHIKV patients have reported increased rates of depression (7–19%),7,9,13,15 hearing 
loss and blurry vision (5–24%),7–9,16 and headaches, dizziness, memory and concentration 
problems (6–22%) beyond the scope of acute infection.7–9  
 
Mother-to-child transmission of CHIKV has been observed among pregnant women having 
symptom onset during the intrapartum period, ±2 days from delivery; the vertical transmission 
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rate for these women has been reported to be 49%.17 While infection early in pregnancy does not 
appear to impact fetal development, neonatal infection with CHIKV is associated with both 
severe acute symptoms and the possibility of long-term developmental delays. Severe acute 
symptoms include encephalopathy (36–47%),17,18 thrombocytopenia (89%),17 febrile seizures,19 
and blistering hyperpigmented rash.20 Neonatal CHIKV infection is associated with delays in 
cognitive development in areas such as coordination, language, movement, and sociability.18 
Particularly poor outcomes are noted for neonates who develop encephalopathy during acute 
infection, with a proportion of these neonates developing conditions such as microcephaly (42%) 
or symptoms matching cerebral palsy (33%).18  
 
These acute and long-term symptoms create a significant economic and disease 
burden for individuals, health systems and societies. There is currently no vaccine for CHIKV or 
any specific treatment; rather, at all stages of disease, guidelines direct physicians to treat 
symptomatically.21 Acetaminophen or similar analgesics are typically used during acute 
infection. Treatments for chronic inflammatory rheumatisms can become costlier due to 
medications and duration and treatment: NSAIDs and first-line disease-modifying antirheumatic 
drug (DMARD) methotrexate are most commonly available in Latin America due to relatively 
low costs, but biologics, which are second-line DMARDs are more expensive and less widely 
accessible.22–24 Beyond the direct costs of medication, several indirect costs are accrued by acute 
and chronic chikungunya: days of missed work due to illness, decreased productivity while at 




Here, we estimate both the burden of disease and the cost of the introduction of CHIKV to the 
Americas. Similar studies have projected the cost of disease in previous outbreaks in La Réunion 
Island,25 in Andhra Pradesh, India,26 and in Colombia during the epidemic in the Americas.27 The 
2014 burden of disease due to chronic inflammatory rheumatism in Latin America has been 
estimated to 151,031–167,950 disability adjusted life years (DALYs),28 but this estimate did not 
account for underreporting, did not include the Caribbean, and did not take into consideration 
varying durations of sequelae. To our awareness, this is the first study to estimate both the 
burden and cost of the chikungunya epidemic in the Americas and the first to consider additional 





We developed data-driven computational simulation models to evaluate the economic cost and 
disease burden for chikungunya in the Americas based on cases reported from 2013−2015, 
accounting for underreporting of disease. For our estimates, we used case counts per country as 
reported by the Pan American Health Organization (PAHO), which are derived from member 
state publications or websites, or from reports from International Health Regulation (IHR) 
National Focal Points (NFP). Confirmed, suspected and imported cases for each country were 
included in our analysis. Confirmed cases tested positive by viral isolation, RT-PCR, anti-
CHIKV IgM detection, or a four-fold increase of anti-CHIKV IgG titers. Suspected cases 
included patients with acute onset fever >38°C and severe arthritis or arthralgia not explained by 
other conditions, and who reside or had visited an area with CHIKV circulation within two 
weeks of symptom onset.2,29  
 
Accounting for Underreporting 
 
Due to the novelty of chikungunya in the Americas, many jurisdictions did not previously have a 
surveillance system for chikungunya. Because of CHIKV’s similar transmission patterns to 
dengue virus (DENV), in many instances, chikungunya surveillance was integrated into existing 
systems for dengue.30–32 Due to absence of widespread data on the underreporting of 
chikungunya, we accounted for underreporting for chikungunya cases using previously recorded 
underreporting rates for dengue, which have varied from by region and time of analysis from 1–
59.33,34 We used an average expansion factor (EF) of 21.65 for our estimates, varying it between 




Estimation of Burden of Disease 
 
For each estimated case that sought care in a country, an individual entered independent models 
where they encountered distributions of probabilities for being an ambulatory or hospitalized 
acute chikungunya case, and for developing chronic inflammatory rheumatism, depression, 
sensorineural problems, or persistent headaches. DALYs, which take into consideration the years 
of life lost (YLL) due to premature mortality and years lived with disability (YLD) from a health 
condition, were used as a measure of burden of disease. Due to the rarity of death from 
chikungunya, we focused our DALY estimates on YLD, which is calculated from a given 
disability weight (DW), years lived with condition, and incidence. We assigned a specific DW 
from the Global Burden of Disease (GBD) Study 2013 to calculate DALYs for acute illness, 
chronic inflammatory rheumatism, cognitive delays from neonatal CHIKV infection, depression, 
sensorineural effects and headaches (Table 1).35 Duration of acute disease was sampled from a 
truncated exponential distribution with a median of 6.3 days and maximum of 21 days. To model 
the distribution of durations for all long-term sequelae aside from neonatal CHIKV, we fit 
regression models using data from published literature between the prevalence of the symptom 
and the study time-point post-acute disease.36 The number of neonatal CHIKV infections were 
estimated using the country-specific birth rates, population sizes, and previously published 
prevalence of vertical transmission and lasting cognitive disabilities.17,18 Country-specific 
average life spans were used for calculating duration of lasting cognitive disabilities.37 DALYs 





Estimation of Costs 
 
We calculated total societal costs for acute illness, chronic inflammatory rheumatism and 
cognitive delays from neonatal infection. We estimated both direct costs from medical treatment 
and indirect costs from either missed work or decreased productivity at work due to disability.  
We did not calculate costs associated with depression, sensorineural problems, and persistent 
headaches, as insufficient data is available in terms of care-seeking behaviors and treatment 
options for these conditions in relation to CHIKV. Each individual in our models encountered 
distributions of probabilities for all treatment events, and all distributions of durations were 
estimated using the same methods as used for DALY calculations. For ambulatory acute 
chikungunya cases, we assumed individuals incurred costs from an outpatient doctor visit, and 
acetaminophen (4g/day) for each day of illness.21 Hospitalized acute chikungunya cases incurred 
costs of hospitalization per day  for their length of stay,13,30,38 as well as cost of acetaminophen 
(4g/day) for their duration of illness.21 
 
The treatment for chronic inflammatory rheumatism was dependent on the duration of pain. All 
chronic inflammatory rheumatisms lasting less than three months accrued costs of NSAIDs 
(celecoxib 200mg/day or ibuprofen 1200 mg/day).22 Although methotrexate, a first-line 
DMARD, is recommended for CHIKV-related arthritis lasting beyond three months,22 we took 
into consideration structural delays in accessing treatment from a rheumatologist in Latin 
America, as described for other joint-related symptoms, such as rheumatoid arthritis.16,39,40 
Additionally, we attempted to take into consideration lack of availability to biologics as a 
second-line treatment, as previously reported in Latin America.40 If individuals had chronic 
inflammatory rheumatism that persisted past when they were able to seek rheumatic care and that 
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was beyond three months, they entered one of three pathways: continuing daily NSAID use, 
switching to methotrexate (15mg/week) with a supplement of folic acid (1mg/day),16,22 or 
beginning using methotrexate for at least three months but switching to biologics due to failed 
methotrexate treatment (Figure 1).16,22 All cases with chronic inflammatory rheumatism lasting 
three months or longer who also accessed rheumatic care received a diagnostic x-ray and 
incurred costs of rheumatologist visits.22 
 
Country-specific costs were used in estimating distribution of costs for medical services. Using 
available data, regression models were fit between country GDP per capita and cost of medical 
service,41 and these models were used to predict cost for countries for which cost data was not 
available. Due to the lack of correlation between cost of medications and GDP per capita, an 
average cost of each medication was taken and used for all countries (Table 1). Costs associated 
with neonatal infection were estimated using previously reported costs for cerebral palsy in the 
United States, and converted into respective country costs by region using comparative 
purchasing power parities.42,43 We used average country monthly wage to estimate indirect 
costs,44 and used estimates for rheumatoid arthritis to predict decreases in productivity and 
missed work for chronic inflammatory rheumatism.45–48 
 
Each input parameter distribution was randomly sampled and events executed for the total 
number of estimated cases in each country. The simulation was run 1,000 times for each country. 
Simulations were performed in R version 3.2.2  and package rworldmap was used for 






We estimate approximately 39.9 million (range: 1.8–108.9 million) CHIKV cases in the 
Americas from 2013–2015, based on PAHO case reports and EF=21.65 (range: 1–59). Our 
simulations projected that the emergence of chikungunya in the Americas has caused 23,824,464 
DALYs and has created a total cost of $185 billion from a societal perspective, including $83.6 
billion in direct costs and $101.4 billion in indirect costs. On average, chronic inflammatory 
rheumatism was the source of 91.0% of DALYs, 96.5% of direct costs, and 94.4% of indirect 
costs. Indirect costs accounted for 54.9% of total costs. The region with with highest burden of 
both cost and disease was the Caribbean, which accounted for 46.4% of total DALYs lost, and 
49.0% of total costs (Figure 2).  
 
Estimation of Direct and Indirect Costs 
 
The total societal cost in the Caribbean was $90.7 billion (range: $87.5–$94.0 billion), in the 
Andean region was $55.4 billion (range: $54.2–$56.8 billion), in Central America was $33.8 
billion (range: $32.4–$35.1 billion), in the Southern Cone was $2.7 billion (range: $1.6–$2.9 
billion) and in North America was $2.4 billion (range: $2.1–$2.7 billion) (Table 2). The 
countries with the highest total cost were Colombia ($45 billion, range: $44.3–$45.7 billion), the 
Dominican Republic ($43.9 billion, range: $43.3–$44.6 billion), and El Salvador ($15.2 billion, 
range: $14.8–$15.6 billion). The Caribbean accounted for 49.0% of all costs, the Andean region 
accounted for 30.0%, Central America accounted for 18.3%, the Southern Cone for 1.4% and 




The per-capita cost for chikungunya in Central America was $737 (range: $709–$762), in the 
Caribbean was $2,042 (range: $1,981–$2,105), in the Southern Cone was $10 (range: $9–$11), 
in the Andean region was $404 (range: $395–412) and in North America was $5 (range: $4.50–
$5.40). Countries and territories with the highest per-capita costs were Saint Barthelemy, 
Martinique, and Guadeloupe (Supplementary Table 1).  
 
Estimation of Disease Burden in DALYs 
 
The average burden of disease was 0.60 (95% Confidence Interval [CI]: 0.41–0.83) DALYs per 
case. The average societal burden of disease was 2,432 (95% CI: 1,656–3,390) DALYs per 
100,000 population, but this varied greatly by region: 24,882 (95% CI: 16,938–34,678) DALYS 
per 100,000 population in the Caribbean, 11,440 (95% CI: 7,788–15,943) DALYs per 100,000 
population in Central America, 5,094 (95% CI: 3,468–7,100) per 100,000 population in the 
Andean region, 122 (95% CI: 83–170) per 100,000 population in the Southern Cone, and 41 
(95% CI: 28–57) per 100,000 population in North America (Figure 2). The countries with the 
highest disease burden per population were Saint Barthelemy, Martinique, and Guadeloupe—all 
in the less Antilles of the Caribbean. Chronic inflammatory rheumatism was the overwhelming 
source of DALYs from chikungunya, as 91.0% of all DALYs were associated with this condition 
 
Total DALYs lost also varied by region: we projected 11,050,521 (95% CI: 
7,522,687−15,400,992) DALYs in the Caribbean, 6,998,121 (95% CI: 4,763,998−9,753,169) 
DALYs in the Andean region, 5,247,959 (95% CI: 3,572,569−7,313,995) DALYs in Central 
America, 331413 (225,610−461,884) DALYs in the Southern Cone, and 196,451 (95% CI: 




Burden and Cost of Neonatal Infection 
 
We estimate approximately 801 cases of neonatal CHIKV through vertical transmission, of 
which 291−379 will develop neonatal encephalopathy in the Americas. Among those with 
neonatal encephalopathy, 97−126 will experience lasting disability similar to cerebral palsy, with 
impacts on their movement, motor skills, and possibly intellectual capabilities. The total lifetime 
cost from a societal perspective for these sequelae is estimated to be $63.3 million (range: $59.4–
$77.3 million). The total burden of disease associated with long-term sequelae from neonatal 




Varying the cost of drugs from the minimum to maximum drug prices resulted in a 18.7% 
decrease and 11.9% increase in overall costs, respectively. Varying the expansion factor to EF=1 
led to a decrease in cost and DALYs lost by 95.4%, and EF=59 led to an increase in cost and 





Our computational simulation model uses data collected from an extensive literature review to 
reveal the substantial economic and disease burden of the introduction and continued spread of 
CHIKV in the Americas: we estimate a societal cost of $185 billion and a burden of 23.8 million 
DALYs through the end of 2015. Chronic inflammatory rheumatism was the source of the vast 
majority of cost and DALYs lost. Geographically, we project that the Caribbean region bears 
nearly half of all cost and burden associated with the epidemic, followed by the Andean region 
and Central America. Not only has the chikungunya epidemic in the Americas created a strain on 
health systems, but our per-case estimates indicate that chronic chikungunya conditions may 
continue to place substantial strains on individuals, even in lower levels of CHIKV transmission. 
 
The association between acute CHIKV infection and chronic inflammatory rheumatism and 
neonatal encephalopathy has been well-established in the literature. While we estimated that only 
97−126 children throughout the Americas will develop lasting disabilities from neonatal 
infection, these sequelae accounted for a societal cost of $63.3 million (range: $59.4–$77.3 
million), which is over $610,000 per case. While disability from neonatal CHIKV is a rare 
outcome among vertically transmitted CHIKV cases, it is severe, costly, and warrants increased 
attention. The links between depression, sensorineural problems and cerebral effects have been 
reported multiple times, but are less thoroughly established. We included them in our analysis in 
order to provide as comprehensive of an investigation into the burden of CHIKV as possible, but 
further investigation is needed to better understand the relationship between these conditions and 
CHIKV. We estimated that depression associated with chikungunya infection accounts for about 
8% of total DALYs, but we do not know if this may arise independently of or synergistically 
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with chronic inflammatory rheumatism. While no specific links have been drawn between 
CHIKV-associated chronic inflammatory rheumatism and depression, past research has reported 
positive correlations between depression and rheumatic disorders.51,52  
 
Our estimates for both cost and DALYs lost due to chikungunya are higher than previous cost-
of-illness studies in previous outbreaks. We believe this is due to our accounting for 
underreporting, our inclusion of other sequelae beyond chronic inflammatory rheumatism, and 
our use of distributions for the durations and prevalence for chronic sequelae, all of which have 
not been performed in prior estimates. In an outbreak in Andhra Pradesh, India, burden of 
disease was estimated to be 0.03 DALYs per case, but the study reported that chronic joint pain 
affected only 4% of individuals lasting for a mean duration of 19 days.26 Few economic and 
disease burdens have been estimated for the epidemic in the Americas, and those that have only 
capture the first year of virus transmission. For Latin America in 2014, one study suggested that 
45.1–50.1% of 855,890 acute CHIKV cases developed chronic inflammatory rheumatism, 
creating 151,031–167,950 DALYs lost, or 0.39 DALYs per case.28 Our per-case estimate of 0.60 
DALYs is slightly higher, potentially due to our use of distributions of chronic rheumatism 
durations instead of a point estimate. Another study in Colombia in 2014 found that chronic 
rheumatic symptoms were responsible for at least 95% of total estimated costs, similar to our 
estimate of 91%.27 However, because this study was conducted before the majority of cases in 
the country occurred, we find higher overall estimates for burden and costs.  
 
The cost and burden of chikungunya proves to be substantial even in comparison to other major 
diseases in the Americas. The annual cost of dengue in the Americas has been estimated to be $2 
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billion per year, causing about 72,277 DALYs annually.33 In just over two years of epidemic 
chikungunya transmission, the cost has been over 46 times that predicted cost of dengue in the 
same period, and over 150 times the number of DALYs, even though dengue’s case fatality rate 
is higher than that of chikungunya. Chagas, a disease with a multi-year chronic phase, is 
estimated to account for approximately 806,170 DALYs and $627.5 million annually.53 In 
countries eligible for the GAVI, the Vaccine Alliance, (Bolivia, Cuba, Guyana, Haiti, Honduras, 
and Nicaragua), it has been estimated that the impact of introducing a vaccine for human 
papilloma virus (HPV), vaccination would save 31,384 DALYS,54 and for rotavirus vaccine 
would save 50,063 DALYs.55 In these same countries, the burden of disease from chikungunya 
during this epidemic was projected to be 3.1 million (2.1−4.3 million) DALYs and cost to be 
$18.6 billion ($17.7−$19.5 billion). Given a sufficient susceptible population, future epidemics 
of chikungunya in the Americas or elsewhere may be possible, and ample efforts should be made 
for prevention measures for this costly disease.  
 
It is likely that we underestimate the true cost and burden of chikungunya in the Americas. First, 
our model only included individuals who sought care for acute infection, omitting a potentially 
significant portion of infected individuals who chose not or were unable to seek medical care. 
Care-seeking behaviors have yet not been well documented for chikungunya: early investigations 
in Puerto Rico and Suriname recorded that 63% of CHIKV-positive and 79.5% of CHIKV-
suspected participants sought care, respectively.30,56 Care-seeking behavior can vary largely by 
region, environment, and economic status,57 which interferes with the ability to accurately 
account for these variations across such a diverse region. Next, we may have underestimated 
total costs for medical services: we used values from the WHO-CHOICE project, which reports 
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costs from the public sector per country,38 excluding often higher costs from services used in the 
private sector, and we did not include costs that might be introduced from physical therapy, 
patient education, surgery or other related medical needs. Finally, we did not include costs of 
vector control, increased surveillance, or loses of tourism revenue, which are all potentially 
important arenas of cost from a society perspective.58  
 
A major strength of our study was the consideration of sequelae beyond chronic inflammatory, 
such as cognitive delays from CHIKV-associated neonatal encephalitis. Furthermore, our use of 
distributions for prevalence and durations of sequelae allows us to model outcomes that reflect 
the uncertainty and variety of real-world disease progression scenarios. Our study also had 
several limitations. First, we did not differentiate between chronic arthralgia and arthritis in 
accounting for treatments for chronic inflammatory rheumatisms. While past studies assessing 
long-term effects of CHIKV infection did not differentiate between these two sequelae, the 
conditions do differ in prevalence and duration; arthritis is rarer than arthralgia, but often 
requires costlier treatments.59 Therefore, by assessing the two in the same manner, we likely 
overestimate the true cost and burden of disease. There are also several limitations in using an 
average expansion factor for dengue in order to account for underreporting of chikungunya. The 
two diseases may have different reporting patterns for a variety of reasons: for instance, as a new 
disease to the region, chikungunya may be more likely to be under-recognized or misdiagnosed, 
doctors may not reliably report cases due to high patients loads, and there may be a lag or deficit 
in reporting chikungunya due to the novel nature of the surveillance system. Surveillance system 
structure varies substantially between and within countries, and using an average underreporting 
factors ignores that heterogeneity. Additionally, we did not account for over-reporting in our 
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analysis, which may contribute to an overestimate of cost and burden of disease: as almost all 
countries report all suspected cases without laboratory confirmation, there are likely to be cases 
reported that are misdiagnosed as CHIKV. We assumed that the progression of treatment and 
medication choices and doses were the same for each country, which may not accurately reflect 
variations in treatment and prescription practices. Finally, estimates on a region or country scale 
overlook heterogeneity of burden or costs within countries.  
 
As demonstrated by CHIKV, when novel viruses transmitted by the Aedes aegypti mosquito are 
introduced to the Americas, they have the potential to rapidly spread through immunologically 
naïve populations and create considerable economic costs and health burdens. Increased efforts 
to implement and design more effective vector control methods would curb the burdens created 
not only by CHIKV, but by DENV, zika virus, and other mosquito-borne pathogens yet to 
emerge or reemerge. Additional efforts to find alternative and less costly methods for treating or 
managing long-term pain caused by CHIKV infection remain important, given the high 
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Tables and Figures 
Table 1. Input parameters values and definitions.  
Definition Values Distribution References 
Probabilities and Duration Distributions 




Length of Hospitalization 3−15 days Uniform 13,30 
Probability of Hospitalization 0.13−0.15 Uniform 14,30 
Probability of Chronic Inflammatory 
Rheumatism 
0.1270−0.6383 Uniform 5–15 
Probability of missing work during acute 
illness 
0.52−1.00 Uniform 61,62 
Decrease in productivity from chronic 
inflammatory rheumatism 
0.07−0.25 Uniform 45,46 
Time absent from work  due to chronic 
inflammatory rheumatism (days lost per 
month) 
0.2−0.344 Uniform  
47,48 
Probability of methotrexate failure and 
commencement of biologics 
0.13 -- 16 
Probability of depression 0.07–0.19 Uniform 7,13,63 
Probability of sensorineural problems 0.05–0.24 Uniform 7–9,16 
Probability of headache 0.06–0.22 Uniform 7–9 
Length of time to seeing rheumatologist 
post-acute disease 
3−24 months Uniform 16,39 
Probability of access to biologics 0.6–1 Uniform 40 
Probability of vertical transmission in a 
pregnancy 
0.0025 -- 17 
Probability of developing severe neonatal 
encephalitis given infection 
0.364−0.474 Uniform 17,18 
DALY Calculations: Disability Weights (DW) 
Acute Illness (DW: Moderate Infectious 
Disease) 
0.051 (95% CI: 
0.032, 0.074) 
 35 
Severe Acute Illness (DW: Severe 
Infection Disease  
0.133 (95% CI: 
0.088, 0.190) 
 35 
Chronic Inflammatory Rheumatism (DW: 
Generalized moderate musculoskeletal 
disorder) 
0.317 (95% CI: 
0.216, 0.440) 
 35 
Depression (DW: Major Depressive 
Disorder, Mild Episode) 
0.145 (95% CI: 
0.099, 0.209) 
 35 
Sensorineural (DW: Moderate Hearing 
Loss)  
0.027 (95%CI: 0.015, 
0.042) 
 35 
Persistent Headache (DW: Tension Type 
Headache) 
0.037 (95% CI: 
0.022, 0.057) 
 35 
Neonatal infection-associated severe 
cognitive disability (DW: Motor and 
Cognitive Impairments Severe) 
0.542 (95% CI: 
0.374, 0.702) 
 35 
Neonatal infection-associated moderate 
cognitive disability (DW: Motor and 
Cognitive Impairments Moderate): 
0.203 (95%CI: 0.134, 
0.290) 
 35 
Medication Costs  
Acetaminophen cost per day (mean, 
range) 
$0.41 ($0.04–$1.32)  64–69 
 
28 
NSAIDs cost per day (mean, range) $0.33 ($0.06–$0.60)  64–67 
Methotrexate cost per week (mean, range) $1.66 ($0.23–$4.26)  64,65,67,68 
Folic Acid cost per day, (mean, range) $0.07 ($0.02–$0.21)  64,65,68 
Biologics cost per week (mean, range) $491.51 ($283.58–
$611.00) 
 65 
Hospitalization Cost, per day Country-specific  38 
Cost per outpatient visit Country-specific  38 
Cost of x-ray Country-specific  70,71 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Model Diagram for the Progression of Treatment for Post-CHIKV Chronic 







Figure 2. Maps of DALYs per population and cost per capita by country in the Americas 





Supplementary Table 1. Country-specific estimates for economic cost and burden of 
disease in the Americas, 2013–2015.  





Total DALYs Total DALYs 
per 100,000 
Total Americas $184,945,005,700 $189 $4,628  23,824,464   2,432  
North America $2,375,166,000 $5 $7,091  196,451   41  
Bermuda $5,816,000 $84 $20,662  164   236  
Canada $62,350,000 $2 $13,519  2,704   8  
Mexico $1,123,000,000 $9 $4,408  149,417   123  




$33,802,188,700 $737 $3,841  5,247,959   11,440  
Belize $258,700 $1 $3,983  38   11  
Costa Rica $32,290,000 $7 $5,232  3,681   75  
El Salvador $15,230,000,000 $2,386 $4,017  2,260,945   35,421  
Guatemala $5,119,000,000 $323 $3,922  778,595   4,909  
Honduras $7,222,000,000 $874 $3,676  1,171,706   14,184  
Nicaragua $6,171,000,000 $1,000 $3,574  1,029,819   16,696  
Panama $27,640,000 $7 $5,189  3,174   81  
Andean Area $55,437,110,000 $404 $4,724  6,998,121   5,094  
Bolivia $87,470,000 $8 $3,797  13,742   127  
Colombia $45,000,000,000 $920 $4,614  5,816,880   11,889  
Ecuador $3,246,000,000 $203 $4,448  435,244   2,723  
Peru $27,640,000 $1 $3,422  3,318   11  
Venezuela $7,076,000,000 $229 $5,788  728,937   2,363  
Southern Cone $2,659,517,000 $10 $4,787  331,413   122  
Argentina $11,220,000 $0 $6,243  1,072   3  
Brazil $2,261,000,000 $11 $4,915  274,371   136  
Chile $3,597,000 $0 $5,933  362   2  
Uruguay $0 $0 $0  -     -    
Paraguay $383,700,000 $55 $4,116  55,607   804  
Caribbean $90,671,024,000 $2,042 $4,893  11,050,521   24,882  
Anguilla $20,480,000 $1,280 $7,220  1,689   10,556  
Antigua and 
Barbuda 
$188,900,000 $2,076 $5,975  18,851   20,716  
Aruba $263,100,000 $2,381 $8,311  18,875   17,082  
Bahamas $18,190,000 $48 $7,778  1,395   365  
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Barbados $257,800,000 $891 $6,370  24,136   8,337  
British Virgin 
Islands 
$89,030,000 $2,739 $10,436  5,088   15,657  
Cayman Islands $91,810,000 $1,669 $15,363  3,564   6,479  
Curacao $409,900,000 $2,779 $7,064  34,597   23,456  
Dominica $379,100,000 $5,193 $4,653  48,583   66,552  
Grenada $328,900,000 $2,990 $4,906  39,982   36,348  
Guyana $465,600,000 $579 $3,971  69,923   8,702  
Jamaica $244,200,000 $87 $6,231  23,384   836  
Montserrat $14,950,000 $2,990 $5,480  1,627   32,541  
Saint Kitts and 
Nevis 
$89,500,000 $1,755 $6,310  8,456   16,581  
Saint Lucia $89,950,000 $552 $4,705  11,401   6,994  
Saint Vincent and 
the Grenadines 
$136,900,000 $1,336 $4,539  17,988   17,549  
Sint Maarten $63,080,000 $1,577 $6,198  6,068   15,171  
Suriname $135,700,000 $250 $5,120  15,803   2,908  
Trinidad and 
Tobago 
$56,930,000 $42 $7,621  4,455   332  
Turks and Caicos 
Islands 
$5,201,000 $106 $9,238  335   684  
US Virgin Islands $414,500,000 $3,986 $10,415  23,732   22,819  
Cuba $1,903,000 $0 $4,394  258   2  
Dominican 
Republic 
$43,920,000,000 $4,172 $3,761  6,962,392   66,132  
French Guiana $3,423,000,000 $13,424 $6,937  294,238   115,387  
Guadeloupe $13,590,000,000 $29,038 $7,674  1,055,808   225,600  
Haiti $4,704,000,000 $450 $3,357  835,591   7,988  
Martinique $12,900,000,000 $31,891 $8,045  956,243   236,401  
Puerto Rico $6,957,000,000 $1,888 $8,984  461,774   12,535  
Saint Barthelemy $453,500,000 $50,389 $11,309  23,908   265,647  
Saint Martin $957,900,000 $26,608 $7,107  80,376   223,267  
 
